Israel China Biotechnology (ICB) Ltd Market Cap ($19.47 Million)
Market Cap & Net Worth: Israel China Biotechnology (ICB) Ltd (ICB)
Israel China Biotechnology (ICB) Ltd market cap. Israel China Biotechnology (ICB) Ltd (TA:ICB) has a market capitalization of $19.47 Million (ILA7.26 Billion) as of October 31, 2026. Listed on the TA stock exchange, this Israel-based company holds position #25094 globally and #363 in its home market, demonstrating a 3.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Israel China Biotechnology (ICB) Ltd's stock price ILA2589.00 by its total outstanding shares 3747710 (3.75 Million).
Israel China Biotechnology (ICB) Ltd Market Cap History (2015–2026)
Israel China Biotechnology (ICB) Ltd market cap history from 2015 to 2026. Data shows growth from $6.21 Million to $26.01 Million (9.21% CAGR). Check today's stock price for Israel China Biotechnology (ICB) Ltd for real-time trading data and today's change.
Israel China Biotechnology (ICB) Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Israel China Biotechnology (ICB) Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see ICB cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
200.47x
Israel China Biotechnology (ICB) Ltd's market cap is 200.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.21 Million | $183.00K | -$4.37 Million | 33.93x | N/A |
| 2016 | $11.21 Million | $96.00K | -$3.85 Million | 116.80x | N/A |
| 2017 | $10.69 Million | $64.00K | -$3.66 Million | 167.04x | N/A |
| 2018 | $4.75 Million | $105.00K | -$3.62 Million | 45.26x | N/A |
| 2019 | $7.03 Million | $139.00K | -$6.41 Million | 50.60x | N/A |
| 2020 | $16.64 Million | $83.00K | -$11.93 Million | 200.47x | N/A |
Competitor Companies of ICB by Market Capitalization
Companies near Israel China Biotechnology (ICB) Ltd in the global market cap rankings as of October 31, 2026. See net asset quality index of Israel China Biotechnology (ICB) Ltd to understand what proportion of total assets are financed by equity.
Key companies related to Israel China Biotechnology (ICB) Ltd by market ranking:
- Meitav Dash Investments Ltd (TA:MTDS): Ranked #8272 globally with a market cap of $1.09 Billion USD ( ILA405.72 Billion ILA).
- Mirae Asset Venture Investment Co. Ltd (KQ:100790): Ranked #14892 globally with a market cap of $283.48 Million USD ( ₩418.30 Billion KRW).
- Aju IB Investment Co. Ltd (KQ:027360): Ranked #16111 globally with a market cap of $216.01 Million USD ( ₩318.75 Billion KRW).
- EBEST Investment & Securities Co. Ltd (KQ:078020): Ranked #16126 globally with a market cap of $214.87 Million USD ( ₩317.06 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8272 | Meitav Dash Investments Ltd | TA:MTDS | $1.09 Billion | ILA11380.00 |
| #14892 | Mirae Asset Venture Investment Co. Ltd | KQ:100790 | $283.48 Million | ₩13640.00 |
| #16111 | Aju IB Investment Co. Ltd | KQ:027360 | $216.01 Million | ₩2685.00 |
| #16126 | EBEST Investment & Securities Co. Ltd | KQ:078020 | $214.87 Million | ₩6210.00 |
Market Capitalization of Israel China Biotechnology (ICB) Ltd (2015–2026)
Market capitalization of Israel China Biotechnology (ICB) Ltd from 2015 to today. Between 2015 and today, Israel China Biotechnology (ICB) Ltd's market cap moved from $6.21 Million to $ 26.01 Million, with a yearly change of 9.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA26.01 Million | +212.68% |
| 2025 | ILA8.32 Million | +104.65% |
| 2024 | ILA4.07 Million | +1.15% |
| 2023 | ILA4.02 Million | +375.62% |
| 2022 | ILA844.99K | -86.84% |
| 2021 | ILA6.42 Million | -61.41% |
| 2020 | ILA16.64 Million | +136.57% |
| 2019 | ILA7.03 Million | +47.99% |
| 2018 | ILA4.75 Million | -55.55% |
| 2017 | ILA10.69 Million | -4.66% |
| 2016 | ILA11.21 Million | +80.58% |
| 2015 | ILA6.21 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Israel China Biotechnology (ICB) Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.47 Million USD |
| MoneyControl | $19.47 Million USD |
| MarketWatch | $19.47 Million USD |
| marketcap.company | $19.47 Million USD |
| Reuters | $19.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.